NVO - Novo Nordisk A/S
51.45 0.00 (0.00%)
After hours: 4:17PM EDT
| Previous Close | 50.89 |
| Open | 50.74 |
| Bid | 51.45 x 800 |
| Ask | 51.45 x 1300 |
| Day's Range | 51.22 - 51.48 |
| 52 Week Range | 41.23 - 51.64 |
| Volume | 957,730 |
| Avg. Volume | 1,384,645 |
| Market Cap | 122.427B |
| Beta (3Y Monthly) | 0.86 |
| PE Ratio (TTM) | 20.90 |
| EPS (TTM) | 2.46 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.27 (2.49%) |
| Ex-Dividend Date | 2018-08-17 |
| 1y Target Est | 49.41 |
- Simply Wall St.•2 days ago
Novo Nordisk A/S (CPH:NOVO B): Ex-Dividend Is In 4 Days
If you are interested in cashing in on Novo Nordisk A/S's (CPH:NOVO B) upcoming dividend of ø5.15 per share, you only have 4 days left to buy the shares beforeRead More...
- Motley Fool•12 days ago
REVIEWAPALOOZA!: 5-Stock Samplers
Learning more about picking, about scoring, and about holding yourself accountable.
- Zacks•13 days ago
Lilly to Bring Half-Priced Version of Popular Humalog Insulin
Eli Lilly (LLY) plans to launch a cheaper version of its popular insulin, Humalog amid increasing pressure to lower drug costs.
- Zacks•14 days ago
What's in the Cards for Aeterna (AEZS) This Earnings Season?
Aeterna (AEZS) growth hormone deficiency test, Macrilen, to drive revenues in the fourth quarter.
- PR Newswire•17 days ago
Novo Nordisk files for a label update for Fiasp® to the EMA and the FDA seeking approval for use in children and adolescents
PLAINSBORO, N.J., March 1, 2019 /PRNewswire/ -- Novo Nordisk today announced that it recently submitted label updates to the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) for Fiasp® (insulin aspart injection) 100 u/mL, seeking approval for use as a new mealtime insulin for children and adolescents with type 1 diabetes. Fiasp® is currently approved to control high blood sugar in adults with diabetes. Managing diabetes around mealtimes can be hard1, with parents of young children with type 1 diabetes reporting that this was one of the most problematic areas2.
- Zacks•19 days ago
Ophthotech's (OPHT) Q4 Loss Wider, Gene Therapy in Focus
Ophthotech (OPHT) reports wider-than-expected loss in the fourth quarter. It boosts gene therapy pipeline through new agreements and acquisitions.
Motley Fool•20 days agoStrongbridge Biopharma plc (SBBP) Q4 2018 Earnings Conference Call Transcript
SBBP earnings call for the period ending December 31, 2018.
- Zacks•24 days ago
Pharma Stock Roundup: MRK Buys IMDZ, FDA Grants Priority Review to Some Candidates
Merck (MRK) to buy Immune Design for $300 million. FDA grants priority review to regulatory applications filed by Merck, Roche (RHHBY) and AbbVie (ABBV).
- Zacks•25 days ago
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
Sector ETF report for PPH
- Zacks•26 days ago
Novo Nordisk Gets FDA Nod for Haemophilia Drug Esperoct
Novo Nordisk (NVO) clinches the FDA approval for its biologics license application in favor of Esperoct to treat adults and children suffering haemophilia A.
- Zacks•last month
Seattle Genetics' Adcetris Gets EC Nod for Label Expansion
Seattle Genetics' (SGEN) partner, Takeda Pharmaceutical receives EC approval for Adcetris in combination with AVD to treat adults with previously untreated CD30+ stage IV cHL.
- GlobeNewswire•last month
Market Trends Toward New Normal in GameStop, Novo Nordisk A/S, Ferroglobe, PC Connection, Nanometrics, and Anavex Life Sciences — Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, Feb. 11, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Zacks•last month
Sanofi (SNY) Q4 Earnings Top, Genzyme Unit Drives Sales Growth
Sanofi (SNY) beat estimates for earnings and missed the same for sales in the fourth quarter. The Specialty Care unit drove top-line growth.
- Motley Fool•last month
Novo Nordisk Is on the Upswing -- for Now
The full year may be a different story.
- Zacks•last month
Sanofi's Myeloma Candidate Meets Goal in Phase III Study
Sanofi's (SNY) late-stage candidate, isatuximab, achieves the primary endpoint in a pivotal study by prolonging progression free survival in patients with relapsed/refractory multiple myeloma.
- Zacks•last month
Merck's Keytruda Clinches CHMP Nod for Difficult Lung Cancer
Merck (MRK) secures a positive verdict from the Committee for Medicinal Products for Human Use to approve Keytruda's combo therapy for first-line treatment of a difficult lung cancer population.
Motley Fool•last monthNovo Nordisk (NVO) Q4 2018 Earnings Conference Call Transcript
NVO earnings call for the period ending December 31, 2018.
- Benzinga•last month
Attention Biotech Investors: Mark Your Calendar For These February PDUFA Dates
The year got off to a slow start for the pharma sector from the perspective of regulatory decisions, with the partial government shutdown not helping matters. FDA Commissioner Scott Gottlieb clarified ...
- The Wall Street Journal•last month
[$$] Danish Drugmaker Expects Higher Working Capital as Brexit Looms
A/S is forecasting a rise in the working capital it would need as it prepares for a potentially disruptive Brexit, including product stockpiles and alternative means of drug transportation. The Bagsvaerd, Denmark-based company is currently storing 16 weeks of drug supply in the U.K. ahead of Britain’s exit from the European Union on March 29. This will result in higher working capital at Novo in the coming quarters, said Mr. Knudsen, without quantifying the potential increase.
- Zacks•last month
Novo Nordisk (NVO) Q4 Earnings Miss Estimates, Revenues Beat
Novo Nordisk (NVO) fourth-quarter 2018 results mainly benefit from strong performance by Ozempic.
- Reuters•last month
Novo Nordisk CEO backs ending drug industry rebate system
COPENHAGEN (Reuters) - The chief executive of drugmaker Novo Nordisk on Friday welcomed a proposal calling for an end to the industry practice of offering after-market discounts called rebates to pharmacy ...
- Associated Press•last month
Novo Nordisk: 4Q Earnings Snapshot
On a per-share basis, the Bagsvaerd, Denmark-based company said it had net income of 54 cents. The drugmaker posted revenue of $4.55 billion in the period. For the year, the company reported profit of ...
- Reuters•last month
Novo Nordisk's new diabetes drug, outlook lift shares
Novo Nordisk reported solid growth for its new diabetes drug on Friday and said it would submit a tablet version, a key growth hope, for U.S. approval in the first quarter, lifting the Danish drugmaker's shares. The world's top maker of diabetes drugs expects 2019 sales growth of 2-5 percent and operating profit growth of 2-6 percent, both measured in local currency. Novo faces pressure on prices from competitors and lawmakers in the United States and is pinning its growth hopes on a once-weekly injection and tablet version of its GLP-1 drug semaglutide for diabetes, as well as anti-obesity treatments.
- Bloomberg•last month
Novo Nordisk CEO Applauds Trump Plan to Limit Rebates
Feb.01 -- Lars Fruergaard Jorgensen, chief executive officer of Novo Nordisk A/S, the world's biggest maker of diabetes drugs, discusses earnings, the company's growth potential, pricing and a proposal by the administration of U.S. President Donald Trump to limit the discounts pharma companies pay middlemen that have been criticized for driving up costs for patients. Jorgensen speaks on "Bloomberg Markets: European Open."
